BriaCell Therapeutics Corp.
BCTX
$3.62
-$0.0292-0.80%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.52M | 6.65M | 8.07M | 8.25M | 8.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.98M | 33.33M | 35.27M | 31.72M | 26.37M |
| Operating Income | -29.98M | -33.33M | -35.27M | -31.72M | -26.37M |
| Income Before Tax | -16.72M | -4.93M | -6.10M | -12.69M | -13.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.72 | -4.93 | -6.10 | -12.69 | -13.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 124.50K | 140.10K | 105.50K | 82.00K | 42.70K |
| Net Income | -16.60M | -4.79M | -6.00M | -12.61M | -13.19M |
| EBIT | -29.98M | -33.33M | -35.27M | -31.72M | -26.37M |
| EBITDA | -29.87M | -33.25M | -35.25M | -31.70M | -26.36M |
| EPS Basic | -13.28 | -4.38 | -5.64 | -11.98 | -12.86 |
| Normalized Basic EPS | -8.26 | -2.69 | -3.49 | -7.46 | -8.02 |
| EPS Diluted | -13.41 | -17.56 | -18.80 | -25.21 | -26.11 |
| Normalized Diluted EPS | -8.26 | -2.83 | -3.63 | -7.60 | -8.17 |
| Average Basic Shares Outstanding | 5.10M | 4.39M | 4.26M | 4.23M | 4.20M |
| Average Diluted Shares Outstanding | 5.10M | 4.43M | 4.30M | 4.27M | 4.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
